All Title Author
Keywords Abstract


Systemic Inflammation and Lung Function Impairment in Morbidly Obese Subjects with the Metabolic Syndrome

DOI: 10.1155/2013/131349

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background. Obesity and asthma are associated. There is a relationship between lung function impairment and the metabolic syndrome. Whether this relationship also exists in the morbidly obese patients is still unknown. Hypothesis. Low-grade systemic inflammation associated with the metabolic syndrome causes inflammation in the lungs and, hence, lung function impairment. Methods. This is cross-sectional study of morbidly obese patients undergoing preoperative screening for bariatric surgery. Metabolic syndrome was assessed according to the revised NCEP-ATP III criteria. Results. A total of 452 patients were included. Patients with the metabolic syndrome ( ) had significantly higher blood monocyte (mean 5.3 versus 4.9, ) and eosinophil percentages (median 1.0 versus 0.8, ), while the total leukocyte count did not differ between the groups. The FEV1/FVC ratio was significantly lower in patients with the metabolic syndrome (76.7% versus 78.2%, ). Blood eosinophils were associated with FEV1/FVC ratio (adj. B ?0.113, ). Conclusion. Although the difference in FEV1/FVC ratio between the groups is relatively small, in this cross-sectional study, and its clinical relevance may be limited, these data indicate that the presence of the metabolic syndrome may influence lung function impairment, through the induction of relative eosinophilia. 1. Introduction Obesity is an increasing worldwide problem that has taken on epidemic proportions [1]. Cross-sectional studies have shown a positive association between obesity and asthma [2]. Weight loss in obese asthma patients improved morbidity and lung function [3]; however, the mechanisms underlying the relationship between asthma and obesity are unclear. It is suggested that low-grade systemic inflammation associated with obesity plays a role. The metabolic syndrome is a common metabolic disorder that may result from the increasing prevalence of obesity. Metabolic syndrome is a cluster of cardiometabolic risk factors characterized by abdominal obesity, insulin resistance, and chronic systemic inflammation [4]. Positive associations with lung function impairment have been reported for components of the metabolic syndrome, such as hypertension [5], type diabetes mellitus [6, 7], low-density lipoprotein cholesterol [8], and overall obesity [9]. In recent large cohort studies, it has been shown that there is also a relationship between lung function impairment and the metabolic syndrome [10–12]. However, all the aforementioned studies included overweight as well as normal weight subjects and were therefore not specifically

References

[1]  WHO, “Obesity and overweight,” Fact Sheet no. 311, 2011, http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
[2]  E. S. Ford, “The epidemiology of obesity and asthma,” The Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 897–909, 2005.
[3]  B. Stenius-Aarniala, T. Poussa, J. Kvarnstr?m, E. L. Gr?nlund, M. Ylikahri, and P. Mustajoki, “Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study,” The British Medical Journal, vol. 320, no. 7238, pp. 827–832, 2000.
[4]  S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition,” Circulation, vol. 109, no. 3, pp. 433–438, 2004.
[5]  J. V. Selby, G. D. Friedman, and C. P. Quesenberry Jr., “Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries,” The American Journal of Epidemiology, vol. 131, no. 6, pp. 1017–1027, 1990.
[6]  E. S. Ford and D. M. Mannino, “Prospective association between lung function and the incidence of diabetes: findings from the national health and nutrition examination survey epidemiologic follow-up study,” Diabetes Care, vol. 27, no. 12, pp. 2966–2970, 2004.
[7]  H. C. Yeh, N. M. Punjabi, N. Y. Wang et al., “Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the atherosclerosis risk in communities (ARIC) study,” Diabetes Care, vol. 31, no. 4, pp. 741–746, 2008.
[8]  D. J. Cirillo, Y. Agrawal, and P. A. Cassano, “Lipids and pulmonary function in the third national health and nutrition examination survey,” The American Journal of Epidemiology, vol. 155, no. 9, pp. 842–848, 2002.
[9]  M. Bottai, F. Pistelli, F. di Pede et al., “Longitudinal changes of body mass index, spirometry and diffusion in a general population,” European Respiratory Journal, vol. 20, no. 3, pp. 665–673, 2002.
[10]  N. Leone, D. Courbon, F. Thomas et al., “Lung function impairment and metabolic syndrome the critical role of abdominal obesity,” American Journal of Respiratory and Critical Care Medicine, vol. 179, no. 6, pp. 509–516, 2009.
[11]  W. Y. Lin, C. A. Yao, H. C. Wang, and K. C. Huang, “Impaired lung function is associated with obesity and metabolic syndrome in adults,” Obesity, vol. 14, no. 9, pp. 1654–1661, 2006.
[12]  B. Naveed, M. D. Weiden, S. Kwon, E. J. Gracely, A. L. Comfort, N. Ferrier, et al., “Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 4, pp. 392–399, 2012.
[13]  M. W. Johns, “A new method for measuring daytime sleepiness: the epworth sleepiness scale,” Sleep, vol. 14, no. 6, pp. 540–545, 1991.
[14]  R. Jones, O. Junghard, J. Dent et al., “Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 10, pp. 1030–1038, 2009.
[15]  M. R. Miller, J. Hankinson, V. Brusasco et al., “Standardisation of spirometry,” European Respiratory Journal, vol. 26, no. 2, pp. 319–338, 2005.
[16]  Y. W. Park, S. Zhu, L. Palaniappan, S. Heshka, M. R. Carnethon, and S. B. Heymsfield, “The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988–1994,” Archives of Internal Medicine, vol. 163, no. 4, pp. 427–436, 2003.
[17]  D. A. Beuther, S. T. Weiss, and E. R. Sutherland, “Obesity and asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 2, pp. 112–119, 2006.
[18]  S. D. Aaron, K. L. Vandemheen, L. P. Boulet et al., “Overdiagnosis of asthma in obese and nonobese adults,” Canadian Medical Association Journal, vol. 179, no. 11, pp. 1121–1131, 2008.
[19]  C. Irace, C. Cortese, E. Fiaschi et al., “Components of the metabolic syndrome and carotid atherosclerosis: role of elevated blood pressure,” Hypertension, vol. 45, no. 4, pp. 597–601, 2005.
[20]  D. J. Kim, J. H. Noh, B. W. Lee et al., “The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population,” Journal of Korean Medical Science, vol. 23, no. 2, pp. 193–198, 2008.
[21]  W. S. Shim, H. J. Kim, E. S. Kang et al., “The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 73, no. 3, pp. 284–291, 2006.
[22]  D. R. Cottam, P. A. Schaefer, G. W. Shaftan, L. Velcu, and L. D. G. Angus, “Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity,” Obesity Surgery, vol. 12, no. 3, pp. 335–342, 2002.
[23]  M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, “Elevated C-reactive protein levels in overweight and obese adults,” Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999.
[24]  T. Ronti, G. Lupattelli, and E. Mannarino, “The endocrine function of adipose tissue: an update,” Clinical Endocrinology, vol. 64, no. 4, pp. 355–365, 2006.
[25]  R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” The New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996.
[26]  H. Kato, S. Ueki, R. Kamada et al., “Leptin has a priming effect on eotaxin-induced human eosinophil chemotaxis,” International Archives of Allergy and Immunology, vol. 155, no. 4, pp. 335–344, 2011.
[27]  S. Conus, A. Bruno, and H. U. Simon, “Leptin is an eosinophil survival factor,” The Journal of Allergy and Clinical Immunology, vol. 116, no. 6, pp. 1228–1234, 2005.
[28]  D. D. Sin and S. F. P. Man, “Impaired lung function and serum leptin in men and women with normal body weight: a population based study,” Thorax, vol. 58, no. 8, pp. 695–698, 2003.
[29]  A. R. Vasudevan, H. Wu, A. M. Xydakis et al., “Eotaxin and obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 256–261, 2006.
[30]  H. J. Kim, C. H. Kim, D. H. Lee et al., “Expression of eotaxin in 3T3-L1 adipocytes and the effects of weight loss in high-fat diet induced obese mice,” Nutrition Research and Practice, vol. 5, no. 1, pp. 11–19, 2011.
[31]  S. Engeli, M. Feldpausch, K. Gorzelniak et al., “Association between adiponectin and mediators of inflammation in obese women,” Diabetes, vol. 52, no. 4, pp. 942–947, 2003.
[32]  F. M. Finucane, J. Luan, N. J. Wareham et al., “Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals,” Diabetologia, vol. 52, no. 11, pp. 2345–2349, 2009.
[33]  J. H. Yoon, J. K. Park, S. S. Oh, K. H. Lee, S. K. Kim, I. J. Cho, et al., “The ratio of serum leptin to adiponectin provides adjunctive information to the risk of metabolic syndrome beyond the homeostasis model assessment insulin resistance: the Korean genomic rural cohort study,” Clinica Chimica Acta, vol. 412, no. 23-24, pp. 2199–2205, 2011.
[34]  E. J. Lee, K. H. In, E. S. Ha et al., “Asthma-like symptoms are increased in the metabolic syndrome,” Journal of Asthma, vol. 46, no. 4, pp. 339–342, 2009.
[35]  B. H. Thuesen, L. L. N. Husemoen, L. G. Hersoug, C. Pisinger, and A. Linneberg, “Insulin resistance as a predictor of incident asthma-like symptoms in adults,” Clinical and Experimental Allergy, vol. 39, no. 5, pp. 700–707, 2009.
[36]  K. M. de Winter-de Groot, C. K. van der Ent, I. Prins, J. M. Tersmette, and C. S. P. M. Uiterwaal, “Exhaled nitric oxide: the missing link between asthma and obesity?” The The Journal of Allergy and Clinical Immunology, vol. 115, no. 2, pp. 419–420, 2005.
[37]  T. J. T. Sutherland, J. O. Cowan, S. Young et al., “The association between obesity and asthma: interactions between systemic and airway inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 5, pp. 469–475, 2008.

Full-Text

comments powered by Disqus